Comparative Pharmacology
Head-to-head clinical analysis: OGEN 2 5 versus OGEN 625.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OGEN 2 5 versus OGEN 625.
OGEN 2.5 vs OGEN .625
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estrogen replacement therapy; binds to estrogen receptors, leading to activation of estrogen-responsive genes and physiological effects mimicking endogenous estrogens.
Estrogen replacement therapy; estrogen binds to estrogen receptors, which then translocate to the nucleus and modulate gene transcription, leading to effects such as proliferation of the endometrium and regulation of gonadotropin secretion.
0.625 mg orally once daily (estropipate 0.75 mg equivalent), cyclic or continuous.
0.625 mg orally once daily
None Documented
None Documented
10-24 hours; terminal half-life may be prolonged in hepatic impairment.
Estrone: 10-24 hours; equilin: 12-18 hours; terminal half-life supports once-daily dosing.
Primarily renal as sulfate and glucuronide conjugates; less than 10% excreted unchanged.
Renal (primarily as glucuronide and sulfate conjugates, ~50-80% of a dose), fecal (~10-20%), with enterohepatic recirculation.
Category C
Category C
Estrogen
Estrogen